Together these data suggest that the association between CD32B + B-CLS and reduced time to metastatic disease might be driven by B-CLS CD32B positivity rather than just the number of B-CLS alone in high BMI patients. The gene discussed is FCGR2B; the disease is metastatic neoplasm.